ABSTRACT
OBJECTIVES: We aimed to describe the efficacy and safety of dalbavancin in treatment of patients with diabetes-related foot osteomyelitis with bone culture confirmation. PATIENTS AND METHODS: Between January 2019 and December 2021, all consecutive patients receiving at least one 1500 mg dose of dalbavancin for diabetes-related foot osteomyelitis were included in a retrospective study. Remission was defined as absence of relapsing infection or need for surgery at the initial or a contiguous site during 6-month follow-up from the last dose of dalbavancin. RESULTS: Thirteen patients were included. Eleven (85%) patients were surgically treated. Six (46%) patients received dalbavancin as first-line treatment and 7 (54%) as second-line treatment due to adverse events related to previous treatments. One adverse event was reported. At 6-month follow-up, 11 patients were evaluable and 9 (82%) were in remission. CONCLUSIONS: In the study, dalbavancin was well-tolerated and showed microbiological and clinical efficacy.
Subject(s)
Diabetes Mellitus , Osteomyelitis , Teicoplanin/analogs & derivatives , Humans , Anti-Bacterial Agents/therapeutic use , Retrospective Studies , Salvage Therapy , Osteomyelitis/drug therapy , Diabetes Mellitus/chemically induced , Diabetes Mellitus/drug therapyABSTRACT
INTRODUCTION: Mycobacterium mucogenicum is a rare but emerging cause of infections, especially in immunocompromised patients. CASE PRESENTATION: We describe a new case of M. mucogenicum catheter-related bloodstream infection in a 34-year-old woman with ovarian cancer. M. mucogenicum was at first considered as a contaminant, and susceptibility testing was not performed. Usual susceptibility of M. mucogenicum motivated prescription of clarithromycin and moxifloxacin. Finally, our isolate was confirmed susceptible to both drugs. Clinical outcome was favorable with no relapse of infection after antibiotics discontinuation despite concomitant chemotherapy. CONCLUSION: Our case illustrates the need for a clinician-microbiologist dialogue in case of suspected M. mucogenicum infection to avoid delaying appropriate management.
Subject(s)
Bacteremia/diagnosis , Catheter-Related Infections/diagnosis , Clinical Laboratory Techniques , Mycobacterium Infections/diagnosis , Nontuberculous Mycobacteria/isolation & purification , Professional Role , Adult , Anti-Bacterial Agents/therapeutic use , Bacteremia/complications , Bacteremia/drug therapy , Bacteremia/microbiology , Carcinoma, Ovarian Epithelial/complications , Carcinoma, Ovarian Epithelial/drug therapy , Carcinoma, Ovarian Epithelial/microbiology , Catheter-Related Infections/complications , Catheter-Related Infections/drug therapy , Clinical Laboratory Techniques/standards , Diagnosis, Differential , Female , Humans , Immunocompromised Host , Microbial Sensitivity Tests , Mycobacterium Infections/complications , Mycobacterium Infections/drug therapy , Nontuberculous Mycobacteria/drug effects , Ovarian Neoplasms/complications , Ovarian Neoplasms/drug therapy , Ovarian Neoplasms/microbiologyABSTRACT
Paraquat is a nonselective contact herbicide of great toxicological importance, being associated with high mortality rates. Because of its high toxicity, the European Union withdrew it from its market in 2007. The aim of this study is to analyze all cases of paraquat poisoning hospitalized in French Guiana in order to assess their incidence and main characteristics.Medical records of all paraquat intoxicated patients hospitalized from 2008 until 2015 were reviewed in this retrospective study.Demographics, clinical presentation, and laboratory data were evaluated.A total of 62 cases were reviewed. The incidence of paraquat poisoning was 3.8/100,000âinhabitants/year. There were 44 adults and 18 children younger than 16 years of age. The median ages were 31 years [18.08-75.25] in adults and 13.4 years [0.75-15.08] in children, respectively. The median duration of hospitalization was longer in children [15.5 days (1-24)] than in adults [2 days (1-30)], Pâ<â.01. The majority of cases was due to self-poisoning (84%).Children had ingested a lower quantity of paraquat [48.8âmg/kg (10-571.1)] than adults [595.8âmg/kg (6-3636.4), Pâ=â.03]. There were more deaths among adults (65%) than in children (22%), Pâ=â.004. The severity and outcome was determined primarily by the amount of paraquat ingested.In conclusion, French Guiana has the largest cohort of paraquat poisonings in the European Union. The major factor affecting the prognosis of patients was the ingested amount of paraquat. The administration of activated charcoal or Pemba, in situ, within the first hour after ingestion of paraquat is essential.
Subject(s)
Drug Overdose/diagnosis , Drug Overdose/therapy , Paraquat/poisoning , Adolescent , Adult , Aged , Charcoal/administration & dosage , Child , Child, Preschool , Dose-Response Relationship, Drug , Drug Overdose/mortality , Female , French Guiana , Humans , Incidence , Infant , Length of Stay/statistics & numerical data , Male , Middle Aged , Prognosis , Retrospective Studies , Suicide, Attempted/statistics & numerical data , Survival Rate , Young AdultABSTRACT
BACKGROUND: Community-onset candidemia constitute a distinct clinical entity the incidence of which is increasing. Contribution of non-albicans Candida species is rising. CASE PRESENTATION: We describe here the first reported case of community acquired fungemia due to Candida pulcherrima. Identification to the species level was performed by MALDI-TOF mass spectrometry. Treatment with fluconazole was successful. CONCLUSION: This case confirms the pathogenic role of C. pulcherrima and the contribution of MALDI-TOF mass spectrometry for identification of rare Candida species.
